Kintor Pharmaceutical Ltd AI Stock Analysis
Want to see HK:9939 full AI Analyst Report?
Kintor Pharmaceutical Ltd (9939) AI Stock Analysis
Kintor Pharmaceutical Ltd
(HKEX:9939)
The stock scores at the bottom of the range due to severe fundamental and technical headwinds. The most significant factor is the company's precarious financial state, marked by massive losses and a high cash burn rate that threatens its viability without additional capital. This is compounded by a bearish technical trend with the stock price in a sustained downtrend below all major moving averages. The negative P/E ratio further confirms a lack of current earnings power.
Kintor Pharmaceutical Ltd (9939) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 684.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 926.27K
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 1.17
- Revenue Growth
- 647.17%
- EPS Growth
- -8.86%
- Country
- Hong Kong
- Employees
- 122
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kintor Pharmaceutical Ltd Business Overview & Revenue Model
Company Description
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on andr...
How the Company Makes Money
Kintor Pharmaceutical Ltd’s business model is typical of a clinical-stage biopharmaceutical developer: it invests in R&D to advance proprietary drug candidates and seeks to monetize them primarily through (i) out-licensing and collaboration arrangeme...
Kintor Pharmaceutical Ltd Financial Statement Overview
Summary
Financial health is critically weak. While revenue grew 169%, the company is deeply unprofitable with a -612% net margin and -$166M free cash flow. Equity is eroding rapidly (-38% YoY), and the cash burn rate, though improved, remains unsustainable without new financing.
Income Statement
28NegativeBalance Sheet
35NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.57M | 32.68M | 5.00M | 0 | 0 | 34.23M |
| Gross Profit | 9.75M | 8.04M | -4.73M | -67.63M | -21.38M | 34.23M |
| EBITDA | -159.18M | -139.23M | -128.37M | -1.05B | -950.74M | -829.09M |
| Net Income | -189.63M | -200.11M | -155.29M | -1.06B | -954.37M | -842.10M |
Balance Sheet | ||||||
| Total Assets | 318.88M | 340.95M | 515.13M | 869.23M | 2.06B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 31.79M | 34.78M | 148.69M | 455.50M | 875.08M | 1.06B |
| Total Debt | 133.56M | 86.64M | 133.01M | 253.92M | 286.39M | 159.73M |
| Total Liabilities | 209.68M | 158.28M | 221.05M | 411.12M | 559.95M | 412.83M |
| Stockholders Equity | 109.20M | 182.67M | 294.08M | 458.11M | 1.50B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | -99.68M | -166.07M | -200.76M | -390.30M | -988.73K | -1.13M |
| Operating Cash Flow | -149.83M | -165.34M | -199.08M | -387.58M | -961.26K | -1.05M |
| Investing Cash Flow | 267.76K | 14.04M | 20.03M | 3.27M | 67.19K | 92.00K |
| Financing Cash Flow | 126.54M | 39.23M | -119.67M | -33.46M | 815.75K | 857.42K |
Kintor Pharmaceutical Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 1.43, below the 50-day MA of 1.66, and below the 200-day MA of 2.27, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 41.64 is Neutral, neither overbought nor oversold. The STOCH value of 54.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9939.
Kintor Pharmaceutical Ltd Peers Comparison
Overall Rating
HK:124452Neutral
HK:996652Neutral
HK:685550.1Neutral
HK:116748Neutral
HK:217140Underperform- HK:993937Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:1244 | 52Neutral | HKD 668.68M | -3.09 | -30.93% | ― | -17.22% | -6.13% |
| HK:9966 | 52Neutral | HKD 5.79B | -28.40 | -10.27% | ― | -31.77% | -177.01% |
| HK:6855 | 50Neutral | HKD 10.85B | -6.14 | -153.78% | ― | 70.26% | -12.79% |
| HK:1167 | 48Neutral | HKD 3.78B | 5.90 | 47.76% | ― | 286.20% | ― |
| HK:2171 | 40Underperform | HKD 6.58B | -55.28 | -9.45% | ― | 68.12% | 81.84% |
| HK:9939 | 37Underperform | HKD 675.74M | -2.88 | -129.93% | ― | 647.17% | -8.86% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9939 | Kintor Pharmaceutical Ltd | 1.39 | -0.77 | -35.65% | |
| HK:9966 | Alphamab Oncology | 5.75 | -4.04 | -41.32% | |
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.51 | -2.36 | -34.28% | |
| HK:1244 | 3D Medicines, Inc. | 2.58 | -2.79 | -51.96% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.44 | -7.04 | -40.27% | |
| HK:6855 | Ascentage Pharma Group International | 28.10 | -37.15 | -56.93% |
Kintor Pharmaceutical Ltd Corporate Events
Kintor Completes Long-Term Safety Trial for KX-826 in China
Kintor Pharmaceutical said it completed follow-up visits in a one-year, long-term safety trial of KX-826 tincture 1.0% for male androgenetic alopecia in China, with favorable safety results. The multicenter, open-label study covered 12 Chinese resear...
Kintor Steps Up Cash-Flow Measures as KX-826 and KOSHINÉ Drive Growth
Kintor Pharmaceutical has outlined progress on measures to resolve a prior auditor’s disclaimer of opinion linked to going-concern uncertainties, focusing on improving operating cash flow and strengthening its financial position. The company is pursu...
Kintor Wins China Patent for Core Skin-Whitening Ingredient KT-939
Kintor Pharmaceutical has received a notice of grant of an invention patent in China for KT-939, its in-house developed tyrosinase inhibitor aimed at inhibiting melanin production. The patent covers both the specific chemical structure and broader co...
Kintor Pharma Reshapes Finance Leadership With New CFO and Process Agent
Kintor Pharmaceutical Limited announced that chief financial officer and joint company secretary Ming Ming Cheung has resigned, also stepping down as the company’s Hong Kong process agent, effective 21 September 2026. The board emphasized that Cheung...
Kintor completes year-long safety trial for whitening ingredient KT-939
Kintor Pharmaceutical announced the successful completion of a year-long human safety trial for KT-939, its in-house developed tyrosinase inhibitor designed for whitening and freckle-removal cosmetic applications. The open-label study followed 114 su...
Kintor Pharmaceutical Boosts Revenue on Cosmetics Push but Stays in the Red
Kintor Pharmaceutical reported a sharp increase in revenue to RMB52.0 million for the six months ended June 30, 2026, up from RMB6.0 million a year earlier, driven mainly by global sales of its new high-end cosmetics brand KOSHINÉ that uses core prod...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026